Abbott Laboratories (NYSE:ABT) had its price objective boosted by Stifel Nicolaus from $49.00 to $51.00 in a research report report published on Wednesday. Stifel Nicolaus currently has a buy rating on the healthcare product maker’s stock.

Other research analysts have also recently issued reports about the stock. Jefferies Group LLC lowered their price target on shares of Abbott Laboratories from $52.00 to $50.00 and set a buy rating on the stock in a report on Tuesday, April 18th. Cowen and Company reissued an outperform rating and issued a $48.00 price target on shares of Abbott Laboratories in a report on Saturday, April 22nd. Royal Bank of Canada reissued a buy rating on shares of Abbott Laboratories in a report on Monday, May 15th. TheStreet cut shares of Abbott Laboratories from a b rating to a c+ rating in a report on Thursday, May 18th. Finally, Zacks Investment Research cut shares of Abbott Laboratories from a buy rating to a hold rating in a report on Wednesday, May 24th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $49.00.

Shares of Abbott Laboratories (NYSE:ABT) opened at 46.62 on Wednesday. The firm has a market capitalization of $80.90 billion, a P/E ratio of 48.51 and a beta of 0.97. The company’s 50-day moving average price is $44.14 and its 200-day moving average price is $42.51. Abbott Laboratories has a 52-week low of $36.76 and a 52-week high of $46.75.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 19th. The healthcare product maker reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.05. The firm had revenue of $6.34 billion for the quarter, compared to analysts’ expectations of $6.16 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The business’s revenue was up 29.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.41 EPS. On average, equities research analysts expect that Abbott Laboratories will post $2.47 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/06/06/abbott-laboratories-abt-price-target-raised-to-51-00-at-stifel-nicolaus.html.

In related news, insider Roger Bird sold 5,600 shares of the stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $43.82, for a total transaction of $245,392.00. Following the sale, the insider now owns 51,313 shares in the company, valued at approximately $2,248,535.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph J. Manning sold 4,200 shares of the stock in a transaction that occurred on Wednesday, April 26th. The stock was sold at an average price of $43.95, for a total transaction of $184,590.00. Following the sale, the insider now owns 26,224 shares in the company, valued at approximately $1,152,544.80. The disclosure for this sale can be found here. Company insiders own 0.26% of the company’s stock.

A number of hedge funds have recently modified their holdings of ABT. Usca Ria LLC raised its stake in shares of Abbott Laboratories by 1.3% in the third quarter. Usca Ria LLC now owns 37,403 shares of the healthcare product maker’s stock worth $1,582,000 after buying an additional 468 shares in the last quarter. Check Capital Management Inc. CA raised its stake in shares of Abbott Laboratories by 9.6% in the third quarter. Check Capital Management Inc. CA now owns 91,476 shares of the healthcare product maker’s stock worth $3,869,000 after buying an additional 8,000 shares in the last quarter. Banco Santander S.A. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $5,189,000. Perceptive Advisors LLC bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $1,921,000. Finally, Sandy Spring Bank raised its stake in shares of Abbott Laboratories by 8.4% in the third quarter. Sandy Spring Bank now owns 117,385 shares of the healthcare product maker’s stock worth $4,992,000 after buying an additional 9,066 shares in the last quarter. Hedge funds and other institutional investors own 62.20% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.